Abstract 77: Analgesic use in relation to sex hormone and prolactin concentrations in premenopausal women.

2012 ◽  
Vol 21 (11 Supplement) ◽  
pp. 77-77
Author(s):  
Scott R. Bauer ◽  
Renee T. Fortner ◽  
Margaret A. Gates ◽  
Heather Eliassen ◽  
Susan E. Hankinson ◽  
...  
2013 ◽  
Vol 24 (6) ◽  
pp. 1087-1097 ◽  
Author(s):  
Scott R. Bauer ◽  
Renée T. Fortner ◽  
Margaret A. Gates ◽  
A. Heather Eliassen ◽  
Susan E. Hankinson ◽  
...  

2014 ◽  
Vol 23 (12) ◽  
pp. 2943-2953 ◽  
Author(s):  
Kelly A. Hirko ◽  
Donna Spiegelman ◽  
Walter C. Willett ◽  
Susan E. Hankinson ◽  
A. Heather Eliassen

2017 ◽  
Vol 42 (8) ◽  
pp. 921-923 ◽  
Author(s):  
C. Bernárdez ◽  
A. M. Molina-Ruiz ◽  
S. Vañó-Galvan ◽  
M. Urech ◽  
D. Saceda-Corralo ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2669
Author(s):  
You Wu ◽  
Susan E. Hankinson ◽  
Stephanie A. Smith-Warner ◽  
Molin Wang ◽  
A. Heather Eliassen

Background: Flavonoids potentially exert anti-cancer effects, as suggested by their chemical structures and supported by animal studies. In observational studies, however, the association between flavonoids and breast cancer, and potential underlying mechanisms, remain unclear. Objective: To examine the relationship between flavonoid intake and sex hormone levels using timed blood samples in follicular and luteal phases in the Nurses’ Health Study II among premenopausal women. Methods: Plasma concentrations of estrogens, androgens, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), prolactin, and sex hormone-binding globulin (SHBG) were measured in samples collected between 1996 and 1999. Average flavonoid were calculated from semiquantitative food frequency questionnaires collected in 1995 and 1999. We used generalized linear models to calculate geometric mean hormone concentrations across categories of the intake of flavonoids and the subclasses. Results: Total flavonoid intake generally was not associated with the hormones of interest. The only significant association was with DHEAS (p-trend = 0.02), which was 11.1% (95% confidence interval (CI): −18.6%, −3.0%) lower comparing the highest vs. lowest quartile of flavonoid intake. In subclass analyses, the highest (vs. lowest) quartile of flavan-3-ol intake was associated with significantly lower DHEAS concentrations (−11.3% with 95% CI: −18.3%, −3.7%, p-trend = 0.01), and anthocyanin intake was associated with a significant inverse trend for DHEA (−18.0% with 95% CI: −27.9%, −6.7%, p-trend = 0.003). Conclusion: Flavonoid intake in this population had limited impact on most plasma sex hormones in premenopausal women. Anthocyanins and flavan-3-ols were associated with lower levels of DHEA and DHEAS.


1999 ◽  
Vol 34 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Margaret C. Martini ◽  
Betsy B. Dancisak ◽  
Carol J. Haggans ◽  
William Thomas ◽  
Joanne L. Slavin

2017 ◽  
Vol 103 (2) ◽  
pp. 497-504 ◽  
Author(s):  
Oliver Pohl ◽  
Line Marchand ◽  
Neil Fawkes ◽  
Jean-Pierre Gotteland ◽  
Ernest Loumaye

Abstract Context OBE2109 is a potent, oral gonadotropin-releasing hormone receptor antagonist being developed for the treatment of sex-hormone–dependent diseases in women. Objective We assessed the pharmacodynamics and safety of OBE2109 alone and combined with estradiol (E2)/norethindrone acetate (NETA) add-back therapy on E2 levels and vaginal bleeding. Design, Setting, and Participants This was a single-center, open-label, randomized, parallel-group study in 76 healthy premenopausal women. Interventions Women were randomly assigned to take the following doses (in milligrams) once daily for 6 weeks: OBE2109, 100 or 200; or OBE2109/E2/NETA, 100/0.5/0.1, or 100/1.0/0.5, or 200/1.0/0.5. Main Outcome Measures E2 concentrations, bleeding pattern, exploratory bone metabolism biomarkers, and adverse events. Results OBE2109 100 mg and 200 mg alone reduced E2 levels to reach median levels of 19.5 and 3.2 pg/mL, respectively, at week 4. Median E2 levels after combined OBE2109/add-back therapy ranged between 25 and 40 pg/mL. OBE2109 100 mg or 200 mg alone induced amenorrhea. By day 15, >85% of women had no vaginal bleeding during the last 4 weeks of treatment. Add-back therapy partially impaired bleeding control: The highest amenorrhea rate (53%) was observed with OBE2109 100 mg/1.0 mg/0.5 mg. The addition of E2/NETA, particularly at 1 mg/0.5 mg, mitigated the increase of two bone markers induced by OBE2109 200 mg. Conclusion OBE2109 promptly lowered E2 levels. Add-back therapy may be required to prevent adverse effects on bone in women treated with the 200-mg dose (at 100 mg in some women). These results provide a basis for OBE2109 regimen selection to treat sex-hormone–dependent diseases.


Sign in / Sign up

Export Citation Format

Share Document